Mervi Aavikko

Mervi Aavikko

Auto-generated profile, based on publicly available information

Mervi Aavikko

Institute of Molecular Medicine Finland (FIMM), Helsinki Institute of Life Sciences (HiLIFE), University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TCTatiana Cajuso
Tatiana Cajuso
PSPäivi Sulo
Päivi Sulo
TTTomas Tanskanen
Tomas Tanskanen
RKRiku Katainen
Riku Katainen
ATAurora Taira
Aurora Taira
LALauri A. Aaltonen
Lauri A. Aaltonen
Genomic instability pathways in colorectal cancer (CRC) have been extensively studied, but the role of retrotransposition in colorectal carcinogenesis remains poorly understood. Although retrotransposons are usually repressed, they become active in several human cancers, in particular those of the gastrointestinal tract. Here we characterize retrotransposon insertions in 202 colorectal tumor whole genomes and investigate their associations with molecular and clinical characteristics. We find highly variable retrotransposon activity among tumors and identify recurrent insertions in 15 known cancer genes. In approximately 1% of the cases we identify insertions in APC, likely to be tumor-initiating events. Insertions are positively associated with the CpG island methylator phenotype and the genomic fraction of allelic imbalance. Clinically, high number of insertions is independently associated with poor disease-specific survival.

19 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
EKEevi Kaasinen
Eevi Kaasinen
OKOuti Kuismin
Outi Kuismin
KRKristiina Rajamäki
Kristiina Rajamäki
HRHeikki Ristolainen
Heikki Ristolainen
MAMervi Aavikko
Mervi Aavikko
LALauri A. Aaltonen
Lauri A. Aaltonen
Clonal hematopoiesis driven by somatic heterozygous TET2 loss is linked to malignant degeneration via consequent aberrant DNA methylation, and possibly to cardiovascular disease via increased cytokine and chemokine expression as reported in mice. Here, we discover a germline TET2 mutation in a lymphoma family. We observe neither unusual predisposition to atherosclerosis nor abnormal pro-inflammatory cytokine or chemokine expression. The latter finding is confirmed in cells from three additional unrelated TET2 germline mutation carriers. The TET2 defect elevates blood DNA methylation levels, especially at active enhancers and cell-type specific regulatory regions with binding sequences of master transcription factors involved in hematopoiesis. The regions display reduced methylation relative to all open chromatin regions in four DNMT3A germline mutation carriers, potentially due to TET2-mediated oxidation. Our findings provide insight into the interplay between epigenetic modulators and transcription factor activity in hematological neoplasia, but do not confirm the putative role of TET2 in atherosclerosis.

26 June 2023 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
EVEssi Viippola
Essi Viippola
SKSara Kuitunen
Sara Kuitunen
RRRodosthenis S Rodosthenous
Rodosthenis S Rodosthenous
AVAndrius Vabalas
Andrius Vabalas
THTuomo Hartonen
Tuomo Hartonen
AGAndrea Ganna
Andrea Ganna
Nationwide health-related registry data provide comprehensive insights into population health and, combined with other data such as demographics, familial relations and socioeconomic data, enable the exploration of various dimensions of human behaviour and health. With the increasing size and variety of available data, advanced statistical and machine learning methods present novel possibilities for prediction and causal inference. 1–3 At the same time, efforts to extract high-quality ‘phenotypes’ from registries, for example clinical endpoints, are needed to provide interpretable results. In this spirit, projects such as the CALIBER initiative have provided curated phenotype definitions based on UK’s primary and secondary health care data. 4 Traditionally, the identification of risk factors and the creation of prediction models for diseases have been conducted using a targeted approach where a specific condition, risk factor or medication is studied for its association with a single disease. Several studies 4–10 have shown the potential of data-driven approaches in examining the associations of a large number of risk factors and thousands of disease trajectories. These studies have been accompanied by an increasing trend towards making the results publicly available through web portals, to enable the re-use of the results by other researchers.

7 August 2012 in Molecular Oncology
Verified
Journal Article
Closed access
PNPenny Nymark
Penny Nymark
MAMervi Aavikko
Mervi Aavikko
JMJussi Mäkilä
Jussi Mäkilä
SRSalla Ruosaari
Salla Ruosaari
THTuija Hienonen-Kempas
Tuija Hienonen-Kempas
EKEeva Kettunen
Eeva Kettunen

17 July 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SRSanni J Rinne
Sanni J Rinne
LSLauri J Sipilä
Lauri J Sipilä
PSPäivi Sulo
Päivi Sulo
EJEmmanuelle Jouanguy
Emmanuelle Jouanguy
Vivien BéziatVivien Béziat
Vivien Béziat
MAMervi Aavikko
Mervi Aavikko
Familial clustering of classic Kaposi sarcoma (CKS) is rare with, approximately 100 families reported to date. We studied 2 consanguineous families, 1 Iranian and 1 Israeli, with multiple cases of adult CKS and without overt underlying immunodeficiency. We performed genome-wide linkage analysis and whole-genome sequencing to discover the putative genetic cause for predisposition. A 9-kb homozygous intronic deletion in RP11-259O2.1 in the Iranian family and 2 homozygous variants, 1 in SCUBE2 and the other in CDHR5, in the Israeli family were identified as possible candidates. The presented variants provide a robust starting point for validation in independent samples.

19 July 2021 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
MAMervi Aavikko
Mervi Aavikko
EKEevi Kaasinen
Eevi Kaasinen
NANoora Andersson
Noora Andersson
NPNalle Pentinmikko
Nalle Pentinmikko
PSPäivi Sulo
Päivi Sulo
LALauri A Aaltonen
Lauri A Aaltonen
Many hereditary cancer syndromes are associated with an increased risk of small and large intestinal adenocarcinomas. However, conditions bearing a high risk to both adenocarcinomas and neuroendocrine tumors are yet to be described. We studied a family with 16 individuals in four generations affected by a wide spectrum of intestinal tumors, including hyperplastic polyps, adenomas, small intestinal neuroendocrine tumors, and colorectal and small intestinal adenocarcinomas. To assess the genetic susceptibility and understand the novel phenotype, we utilized multiple molecular methods, including whole genome sequencing, RNA sequencing, single cell sequencing, RNA in situ hybridization and organoid culture. We detected a heterozygous deletion at the cystic fibrosis locus (7q31.2) perfectly segregating with the intestinal tumor predisposition in the family. The deletion removes a topologically associating domain border between CFTR and WNT2, aberrantly activating WNT2 in the intestinal epithelium. These consequences suggest that the deletion predisposes to small intestinal neuroendocrine tumors and small and large intestinal adenocarcinomas, and reveals the broad tumorigenic effects of aberrant WNT activation in the human intestine.